Showing 3151-3160 of 4166 results for "".
- The Alliance for Healthcare from the Eye Launches to Transform Disease Detectionhttps://modernod.com/news/the-alliance-for-healthcare-from-the-eye-launches-to-transform-disease-detection/2482801/A coalition of healthcare leaders announced the launch of the 'Alliance for Healthcare from the Eye (AHE)' at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City. AHE is a cross-sector initiative
- FDA Approves Neurotech's Encelto as First and Only FDA-Approved Treatment for MacTelhttps://modernod.com/news/fda-approves-neurotechs-encelto-as-first-and-only-fda-approved-treatment-for-mactel/2482690/Neurotech Pharmaceuticals announced that the FDA has approved Encelto (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel). MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision
- Resolving a Seeming Contradiction, Study Advances Understanding of Visual Recognition Memoryhttps://modernod.com/news/resolving-a-seeming-contradiction-study-advances-understanding-of-visual-recognition-memory/2481866/Researchers from The Picower Institute for Learning and Memory have published a study evaluating how our vision is so good at recognizing what’s familiar. The study, published in the Journa
- Study Uncovers Novel Synaptic Intricacies Inside the Retinahttps://modernod.com/news/study-uncovers-novel-synaptic-intricacies-inside-the-retina/2481687/A Northwestern Medicine study has uncovered novel cellular mechanisms within the retina, findings that researchers say could help advance the development of targeted therapeutics for diseases and conditions impacting vision. The findings were
- CORE Publishes Resource on Ectatic Corneal Diseaseshttps://modernod.com/news/core-publishes-resource-on-ectatic-corneal-diseases/2481670/As ectatic corneal diseases—such as keratoconus—pose significant challenges to vision and quality of life, the Centre for Ocular Research & Education (CORE) has dedicated Issue 72 of
- Graybug Announces Review of Strategic Alternativeshttps://modernod.com/news/graybug-announces-review-of-strategic-alternatives/2480935/Graybug Vision announced that its Board of Directors will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. As part of this process, the company will explore the potential for an acquisition, company sale, merger, divesti
- C. Light Technologies Announces Activities and New Partnerships at ARVOhttps://modernod.com/news/c-light-technologies-announces-activities-and-new-partnerships-at-arvo/2480821/At this year’s Association for Research in Vision and Ophthalmology (ARVO), C. Light Technologies will meet with colleagues at booth #2424 to share engineering and software development updates from their new pipeline instrument,
- Graybug to Present at the 2022 ASCRS Annual Meetinghttps://modernod.com/news/graybug-to-present-at-the-2022-ascrs-annual-meeting/2480770/Graybug Vision announced a platform presentation at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, to be held in Washington, D.C. from April 22-26, 2022. Information is listed below and available on the
- Lighthouse Guild to Launch New Technology Center For Blind and Visually Impaired in Manhattanhttps://modernod.com/news/lighthouse-guild-to-launch-new-technology-center-in-manhattan/2480669/Lighthouse Guild is launching its new Technology Center with a special event led by Calvin Roberts, MD, and featuring demonstrations and discussion from Lighthouse Guild clients, community leaders, and vision loss experts,
- Gentex Announces Partnership With eSight To Develop Next Generation Digital Eyewearhttps://modernod.com/news/gentex-announces-partnership-with-esight-to-develop-next-generation-digital-eyewear/2480538/Gentex announced that it is partnering with eSight, provider of vision enhancement technology, to develop and manufacture the next generation of mobile electronic eyewear designed to help people living with visual impairments. Terms of the d
